Craneware's FY25 results show a 52% profit surge and a rejected £26.50/share takeover bid, highlighting strong growth and strategic confidence.
This article covers information on Craneware plc.
LON:CRWCraneware’s FY25 numbers show a business leaning into its strengths in US hospital finance software. Revenue rose 9% to $205.7m, margins edged up, and statutory profit before tax jumped 52% to $24.0m. Behind the headline figures: stronger expansion with existing customers, improving contract quality and a growing contribution from the Trisus platform and 340B “Shelter” programme.
The Board also disclosed – and rejected – an unsolicited approach at £26.50 per share during the year, signalling clear confidence in the strategy and medium-term growth potential.
| Metric | FY25 | FY24 | Change |
|---|---|---|---|
| Revenue | $205.7m | $189.3m | +9% |
| Annual Recurring Revenue (ARR) | $184.0m | $172.0m | +7% |
| Net Revenue Retention (NRR) | 107% | 98% | +9ppt |
| Adjusted EBITDA | $65.3m | $58.3m | +12% |
| Adjusted EBITDA margin | 32% | 31% | +1ppt |
| Statutory profit before tax | $24.0m | $15.7m | +52% |
| Adjusted basic EPS | 116.1 cents | 94.8 cents | +22.5% |
| Basic EPS | 56.2 cents | 33.5 cents | +68% |
| Operating cash conversion | 94% | 90% | +4ppt |
| Total cash | $55.9m | $34.6m | +61% |
| Total bank debt | $27.7m | $35.4m | -$7.7m |
| Gross margin | 87% | 86% | +1ppt |
| Total dividend | 32.0p | 29.0p | +10% |
Two commercial indicators stand out. First, customer retention stayed above 90%, which is excellent by software standards. Secondly, expansion sales to existing customers made up 98% of new sales (FY24: 83%). That tells you hospitals are buying more modules and rolling Trisus out across wider networks.
ARR rose 7% to $184.0m and Net Revenue Retention improved to 107%. Quick refresher: ARR is the annualised value of subscription and other recurring revenues at period-end. NRR measures how revenue from the same customer set changes over a year after churn and upsells – over 100% means the base is expanding. Craneware’s 107% shows upsell comfortably outweighed any attrition.
The Trisus platform is doing heavier lifting. Non-recurring platform revenues increased to $20.0m (FY24: $13.8m), with the 340B “Shelter” programme a key contributor. Importantly, customers are now transitioning Shelter to a recurring model, adding to ARR as planned.
The strategic partnership with Microsoft advanced: 13 Trisus solutions are now on Azure Marketplace, first customer contracts have been signed through the Marketplace, and joint go-to-market activities have begun. Trisus Chargemaster – Craneware’s flagship revenue integrity tool – received Microsoft “AI for Healthcare” certification and retained “Best in KLAS”.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
40 viewsLikes
No ratings yet
During the year, Craneware launched Trisus Assist, an AI-powered assistant initially embedded in Chargemaster, now being rolled out across product sets including 340B. The combination of proprietary data from 200+ million patient encounters and Microsoft’s tooling is a differentiator, in my view, particularly as US providers look for fast, measurable ROI rather than moonshots.
Cash generation remains a hallmark. Operating cash conversion was 94% of Adjusted EBITDA. Cash rose to $55.9m while total bank debt reduced to $27.7m. On the company’s alternative metrics, that puts Craneware in a net cash position of $28.2m at year-end.
After the period, Craneware secured a new unsecured $100m revolving credit facility on improved terms, with an additional $100m accordion and options to extend. That replaces the previous term loan and RCF and lowers interest costs – helpful for both optionality and earnings quality.
The Board proposed a final dividend of 18.5p per share (FY24: 16.0p), taking the total to 32.0p (FY24: 29.0p), up 10%. The subscription model is doing what it should: contracted recurring revenue hit $176.2m (FY24: $168.3m), and the backlog of unsatisfied performance obligations stood at $326.2m, with $128.6m expected to be recognised within one year.
During H2, the company received an unsolicited outline proposal to acquire Craneware at £26.50 per share. The Board did not enter formal negotiations and unanimously rejected the approach in June, restating confidence in the company’s prospects. Shareholder feedback post-announcement was described as supportive.
Takeaway: management believes there is more value to create independently, backed by an accelerating growth profile, stronger margins and the Microsoft alliance.
Management says trading in the first months of the new year has started well, and the combined ARR/NRR gains provide confidence in “continued growth acceleration” in FY26. The balance sheet and new credit facility give room to invest and consider acquisitions that add data, customers, expertise or US‑relevant applications.
This is a high-quality update from Craneware. The model is doing the heavy lifting – sticky customers, expanding deployments and improving economics. The Microsoft alliance and AI credentials are more than marketing gloss; they are beginning to move the commercial needle. The valuation question sits outside this RNS, but the Board’s rejection of a £26.50 approach tells you where they think the runway leads.
Net-net: momentum up, balance sheet stronger, dividend higher. If ARR growth does indeed accelerate as platform revenues convert to subscriptions, FY26 could mark the inflection the Board is aiming for.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.